[1]
Jones CM,Christensen A,Gladden RM, Increases in prescription opioid injection abuse among treatment admissions in the United States, 2004-2013. Drug and alcohol dependence. 2017 Jul 1 [PubMed PMID: 28531769]
[2]
Irwin A,Jozaghi E,Weir BW,Allen ST,Lindsay A,Sherman SG, Mitigating the heroin crisis in Baltimore, MD, USA: a cost-benefit analysis of a hypothetical supervised injection facility. Harm reduction journal. 2017 May 12 [PubMed PMID: 28532488]
[3]
Love SA,Lelinski J,Kloss J,Middleton O,Apple FS, Heroin-related Deaths from the Hennepin County Medical Examiner's Office from 2004 Through 2015. Journal of forensic sciences. 2018 Jan [PubMed PMID: 28422290]
[4]
Darke S,Duflou J, The toxicology of heroin-related death: estimating survival times. Addiction (Abingdon, England). 2016 Sep [PubMed PMID: 27082514]
[5]
Roxburgh A,Darke S,Salmon AM,Dobbins T,Jauncey M, Frequency and severity of non-fatal opioid overdoses among clients attending the Sydney Medically Supervised Injecting Centre. Drug and alcohol dependence. 2017 Jul 1 [PubMed PMID: 28535454]
[6]
Hedegaard H,Warner M,Minino AM, Drug Overdose Deaths in the United States, 1999-2015. NCHS data brief. 2017 Feb [PubMed PMID: 28256996]
[7]
LaForge KS,Yuferov V,Kreek MJ, Opioid receptor and peptide gene polymorphisms: potential implications for addictions. European journal of pharmacology. 2000 Dec 27 [PubMed PMID: 11134674]
[8]
Kreek MJ,Bart G,Lilly C,LaForge KS,Nielsen DA, Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacological reviews. 2005 Mar [PubMed PMID: 15734726]
[9]
Bazoukis G,Spiliopoulou A,Mourouzis K,Grigoropoulou P,Yalouris A, Non-cardiogenic pulmonary edema, rhabdomyolysis and myocardial injury following heroin inhalation: a case report. Hippokratia. 2016 Jan-Mar; [PubMed PMID: 27895451]
[10]
Riccardello GJ Jr,Maldjian PD, Pulmonary hemorrhage in acute heroin overdose: a report of two cases. Emergency radiology. 2017 Dec; [PubMed PMID: 28674923]
[11]
Büttner A,Mall G,Penning R,Weis S, The neuropathology of heroin abuse. Forensic science international. 2000 Sep 11; [PubMed PMID: 10978659]
[12]
Jones JD,Campbell A,Metz VE,Comer SD, No evidence of compensatory drug use risk behavior among heroin users after receiving take-home naloxone. Addictive behaviors. 2017 Aug [PubMed PMID: 28325710]
[13]
Pavarin RM,Fioritti A,Sanchini S, Mortality trends among heroin users treated between 1975 and 2013 in Northern Italy: Results of a longitudinal study. Journal of substance abuse treatment. 2017 Jun [PubMed PMID: 28237351]
[14]
Yu E,Miotto K,Akerele E,Montgomery A,Elkashef A,Walsh R,Montoya I,Fischman MW,Collins J,McSherry F,Boardman K,Davies DK,O'Brien CP,Ling W,Kleber H,Herman BH, A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal. Drug and alcohol dependence. 2008 Sep 1 [PubMed PMID: 18508207]
[16]
Ellis AD,McGwin G,Davis GG,Dye DW, Identifying cases of heroin toxicity where 6-acetylmorphine (6-AM) is not detected by toxicological analyses. Forensic science, medicine, and pathology. 2016 Sep [PubMed PMID: 27114260]
[17]
Melanson SE,Baskin L,Magnani B,Kwong TC,Dizon A,Wu AH, Interpretation and utility of drug of abuse immunoassays: lessons from laboratory drug testing surveys. Archives of pathology & laboratory medicine. 2010 May [PubMed PMID: 20441504]
[18]
Mundin G,McDonald R,Smith K,Harris S,Strang J, Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal. Addiction (Abingdon, England). 2017 Sep [PubMed PMID: 28430384]
[19]
Avetian GK,Fiuty P,Mazzella S,Koppa D,Heye V,Hebbar P, Use of naloxone nasal spray 4 mg in the community setting: a survey of use by community organizations. Current medical research and opinion. 2018 Apr [PubMed PMID: 28535115]
[20]
Willman MW,Liss DB,Schwarz ES,Mullins ME, Do heroin overdose patients require observation after receiving naloxone? Clinical toxicology (Philadelphia, Pa.). 2017 Feb [PubMed PMID: 27849133]
[21]
Leen JLS,Juurlink DN, Carfentanil: a narrative review of its pharmacology and public health concerns. Canadian journal of anaesthesia = Journal canadien d'anesthesie. 2019 Jan 21; [PubMed PMID: 30666589]
[22]
Fiorentin TR,Krotulski AJ,Martin DM,Browne T,Triplett J,Conti T,Logan BK, Detection of Cutting Agents in Drug-Positive Seized Exhibits within the United States. Journal of forensic sciences. 2018 Nov 28; [PubMed PMID: 30485426]
[24]
Smith DE, Medicalizing the Opioid Epidemic in the U.S. in the Era of Health Care Reform. Journal of psychoactive drugs. 2017 Apr-Jun [PubMed PMID: 28296623]
[25]
Fomin D,Baranauskaite V,Usaviciene E,Sumkovskaja A,Laima S,Jasulaitis A,Minkuviene ZN,Chmieliauskas S,Stasiuniene J, Human deaths from drug overdoses with carfentanyl involvement-new rising problem in forensic medicine: A STROBE-compliant retrospective study. Medicine. 2018 Nov; [PubMed PMID: 30508965]
[26]
Goldberg SA,Dworkis DA,Liao VT,Eyre AJ,Albert J,Fawcett MM,Narovec CM,DiClemente J,Weiner SG, Feasibility of Bystander Administration of Public-Access Naloxone for Opioid Overdose. Prehospital emergency care : official journal of the National Association of EMS Physicians and the National Association of State EMS Directors. 2018 Nov-Dec; [PubMed PMID: 29723076]
[27]
Stam NC,Gerostamoulos D,Smith K,Pilgrim JL,Drummer OH, Challenges with take-home naloxone in reducing heroin mortality: a review of fatal heroin overdose cases in Victoria, Australia. Clinical toxicology (Philadelphia, Pa.). 2018 Nov 17; [PubMed PMID: 30451007]
[28]
Saxon AJ,Akerman SC,Liu CC,Sullivan MA,Silverman BL,Vocci FJ, Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry. Addiction (Abingdon, England). 2018 Aug; [PubMed PMID: 29493836]
[29]
Lee JD,Nunes EV Jr,Novo P,Bachrach K,Bailey GL,Bhatt S,Farkas S,Fishman M,Gauthier P,Hodgkins CC,King J,Lindblad R,Liu D,Matthews AG,May J,Peavy KM,Ross S,Salazar D,Schkolnik P,Shmueli-Blumberg D,Stablein D,Subramaniam G,Rotrosen J, Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet (London, England). 2018 Jan 27; [PubMed PMID: 29150198]
[30]
Volkow ND,Jones EB,Einstein EB,Wargo EM, Prevention and Treatment of Opioid Misuse and Addiction: A Review. JAMA psychiatry. 2018 Dec 5; [PubMed PMID: 30516809]
[32]
Moiseev VS,Kobalava ZD,Pisaryuk AS,Milto AS,Kotova EO,Karaulova YL,Kahktsyan PV,Chukalin AS,Balatskiy AV,Safarova AF,Ratchina SА,Merai IA,Povalyaev NM, Infective Endocarditis in Moscow General Hospital: Clinical Characteristics and Outcomes (Single-Center 7 Years’ Experience). Kardiologiia. 2018 Dec 25; [PubMed PMID: 30625099]
[33]
Bandaru S,Manthri S,Sundareshan V,Prakash V, Empyema Necessitans in the Setting of Methicillin-Susceptible {i}Staphylococcus aureus{/i} Causing Pneumonia and Bacteremia. Case reports in infectious diseases. 2018; [PubMed PMID: 29850305]
[34]
Jiang Z,Xiu C,Yang J,Zhang X,Liu M,Chen X,Liu D, HIV test uptake and related factors amongst heterosexual drug users in Shandong province, China. PloS one. 2018; [PubMed PMID: 30335766]
[35]
Faul M,Lurie P,Kinsman JM,Dailey MW,Crabaugh C,Sasser SM, Multiple Naloxone Administrations Among Emergency Medical Service Providers is Increasing. Prehospital emergency care : official journal of the National Association of EMS Physicians and the National Association of State EMS Directors. 2017 Jul-Aug [PubMed PMID: 28481656]
[36]
Chang G,Davids M,Kershaw A, Overdose education and naloxone distribution for veterans with opioid use disorder: Results from a pilot initiative. Journal of addictive diseases. 2017 Oct-Dec [PubMed PMID: 28548574]
[37]
Morton KJ,Harrand B,Floyd CC,Schaefer C,Acosta J,Logan BC,Clark K, Pharmacy-based statewide naloxone distribution: A novel "top-down, bottom-up" approach. Journal of the American Pharmacists Association : JAPhA. 2017 Mar - Apr [PubMed PMID: 28292508]
[38]
Wakeman SE, Another Senseless Death - The Case for Supervised Injection Facilities. The New England journal of medicine. 2017 Mar 16 [PubMed PMID: 28296603]
[39]
Ober AJ,Watkins KE,McCullough CM,Setodji CM,Osilla K,Hunter SB, Patient predictors of substance use disorder treatment initiation in primary care. Journal of substance abuse treatment. 2018 Jul; [PubMed PMID: 29866385]